Is Belkyra right for me?
Belkyra is perfect for both men and women who want to correct a double chin and or fullness under the chin without surgery.
How does Belkyra work?
Belkyra has an active ingredient known as deoxycholic acid. Deoxycholic acid is a naturally-occurring molecule in the body that aids in the breakdown and absorption of dietary fat. When injected in the fat beneath the chin Belkyra destroys the fat cells resulting in a noticeable reduction in fullness.
How long does the treatment take?
A Belkyra treatment takes about 30 minutes. The area underneath the chin is marked with a grid containing small dots to target the specific area. You will then receive multiple small injections under your chin ensuring that the product is dispersed evenly resulting in uniform resorption of fat.
How many treatments will I require with Belkyra?
The number of treatments necessary to reach your desired result will vary from patient to patient. Each treatment is spaced at least 4 weeks apart until the desired result is achieved. Most patients require 3 treatments.
Will I be able to return to work or my normal activities after a treatment?
You will have some swelling and possible bruising under you chin. You may also experience redness in the area. Downtime is typically 1-3 days.
When will I see results?
Patients usually see improvement 4-6 weeks after their first treatment. Though to achieve optimal results 2 to 3 follow up treatments may be needed.
How long will my results last?
Once the fat cells have been destroyed with Belkyra these cells can no longer store or accumulate fat. The cells are gone permanently. It is possible for the remaining cells to grow with weight gain, so maintaining a stable weight following treatment will help to ensure long term results.
How much does the Belkyra treatment cost?
The cost will depend on the number of vials needed to complete a treatment. This will depend on the amount of fat that you have to be removed. Typically, two vials are necessary at an average price of $650-$750 per vial.